Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Teva and Takeda Partner To Meet Demand For Generics In Japan

XTALKS NEWS

Generic

Japan is said to be one of the fastest growing generics markets in the world, and in light of the Japanese government’s determination to decrease healthcare expenditures, the public will require greater access to generic medicines.

Share this!

December 2, 2015 | by Sarah Massey, M.Sc.

Yesterday, Teva Pharmaceutical Industries Ltd. and Takeda Pharmaceutical Company Limited announced their intention to form a partnership, with a focus on providing generics to the Japanese market. The partnership is certainly a strategic move for both companies; Takeda has an illustrious history as a leader in Japan’s pharmaceutical R&D industry, while Teva is regarded as one of the top ten pharmaceutical companies in the world, known for leading the pack in the generics space.

Japan is said to be one of the fastest growing generics markets in the world, and in light of the Japanese government’s determination to decrease healthcare expenditures, the public will require greater access to generic medicines. Takeda’s presence on the Japanese market, in combination with Teva’s multiple areas of expertise – including supply chain, R&D and operational network – have some calling the collaboration “unprecedented in Japan.”

As with any collaborative agreement, the partnership is subject to a number of regulatory approvals. The companies say they expect operations to commence in the second calendar quarter of 2016. Patients will have access to Teva’s generic medicines along with a number of Takeda’s products.

Teva is set to have a controlling share of 51 percent in the joint venture, while Takeda will have a 49 percent stake. The companies have also said that the collaborative entity will operate as a separate company complete with its own Board of Directors, Chief Executive Officer, and Executive Leadership team.



“We are delighted to partner with Teva to start the new business in Japan,” said Dr. Masato Iwasaki, President of Takeda’s Japan Pharma Business Unit. “Takeda will further strengthen its initiative as a leading company in the Japanese pharmaceutical industry, leveraging our activities to lead innovation in medicine as well as supporting the new company's business.”

The companies point out that because the expected start of the partnership is well into 2016, they don’t expect the joint venture to generate any significant financial revenue by the end of the 2015 calendar year. “The new business venture will combine Teva's strong generics platform, portfolio and quality across the value chain with Takeda's leading brand presence and distribution capabilities in Japan,” said the President and CEO of Teva Global Generic Medicines, Siggi Olafsson.

“This unique combination will create a company ideally positioned to lead the high growth in the generic market in Japan and is aligned with the Japanese government objectives to reach 80% generic penetration by the end of fiscal year 2020,” said Olafsson. “The new business venture with Takeda reaffirms our long standing commitment to Japanese patients and delivers on Teva’s strategy of increasing our presence in key emerging markets to position Teva for long-term sustainable growth.”

Sources:

WATCH & PARTICIPATE IN THESE WEBINARS 


 

Chemical Synthesis of Glycosylated Peptides and Proteins Improves Drug Properties

Structural Basis for HCV RNA Replication and Inhibition by Sofosbuvir


Keywords: Generic, Japan, Partnership


| NEXT ARTICLE | MORE NEWS |

Share this with your colleagues!

READ THESE NEXT
FDA Approves First Adjuvant-Containing Influenza Vaccine

December 1, 2015 - Last week, the US Food and Drug Administration (FDA) approved a seasonal influenza vaccine – Fluad – which is the first of its kind to contain an adjuvant.


Immunotherapy Safety Trial For Type 1 Diabetes Deemed A Success

November 30, 2015 - Researchers at the University of California-San Francisco (UCSF) led the first US safety trial of immunotherapy for patients with type 1 diabetes, and found that trial participants experienced no serious adverse reactions to the treatment.


Dr. Reddy’s Laboratory Receives FDA Warning Letter

November 30, 2015 - India-based drugmaker Dr. Reddy’s Laboratories has received a warning letter in which the US Food and Drug Administration (FDA) cites incidents of data manipulation, and potential contamination issues.


LEAVE A COMMENT
 
Copyright © 2016-2017 Honeycomb Worldwide Inc.